Oncology Corporate Profile
The Helsinn Group, a Company focused on building quality cancer care, announces that anamorelin, its novel, once-daily ghrelin receptor agonist significantly increased lean body mass (LBM) compared with placebo in two Phase III trials comprising the largest trial program of its kind to date in non-small cell lung cancer (NSCLC) patients with cachexia, an area of significant unmet medical need.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|anaomrelin||ghrelin receiptor agonist||Acute Myelogenous Leukemia (AML)||III|
|anaomrelin||ghrelin receiptor agonist||Myelodysplastic Syndrome (MDS)||II|
View additional information on product candidates here »